Compare Plby Group Inc (PLBY) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Recursion Pharmaceuticals Inc — how do they compare? Plby Group Inc trades at $1.16 (market cap $141.97M), while Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 13.1× Plby Group Inc's market cap. Which is the better fit depends on your goals.
| PLBY | RXRX | |
|---|---|---|
Market Cap | $141.97M | $1.86B |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $6.79 |
52-Week Low | $1.11 | $2.84 |
Enterprise Value | $287.56M | $1.38B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY Group trades at $1.18, showing modest daily gains but remains in a technical downtrend. The company demonstrates improving fundamentals with revenue stabilizing around $120M and narrowing losses, though profitability remains elusive. Recent positive developments include Q2 2026 earnings beat, inclusion in Russell indexes, and strategic share repurchases. Analyst sentiment leans bullish with 75% buy ratings, yet technical indicators signal caution with bearish moving averages.
The outlook suggests cautious optimism as PLBY transitions toward profitability, supported by licensing growth and cost management. Key opportunities include brand monetization and market share gains, while risks involve high debt levels, negative equity, and competitive pressures. Investors should monitor execution on profitability targets and debt reduction progress for sustained recovery.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
